Literature DB >> 21514148

Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.

Refika Yigit1, Carl G Figdor, Petra L M Zusterzeel, Jeanette M Pots, Ruurd Torensma, Leon F A G Massuger.   

Abstract

Epithelial ovarian cancer (EOC) is an immunogenic tumour and exploits many suppressive ways to escape immune eradication. EOC is known to spread primarily by tumour cell implantations in peritoneal cavity. Therefore, ascites may be an ideal fluid compartment to unravel the immune status of the peritoneal cavity. We analysed the expression of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IFN-γ, TNF-α, TNF-β, TGF-β and CCL22 in ovarian cancer ascites, representing immune activating and suppressing cytokines. We observed high expression of pro-inflammatory cytokines IL-6, IL-8 and immune suppressive cytokines IL-10, CCL22 and TGF-β in most samples whereas Th1 (IL-12p70, IFN-γ) and Th2 (IL-4, IL-5) cytokines were only detectable in 13% of the samples. TGF-β was only detected in latent form, questioning its immune suppressive role. CCL22 was in similar levels present in early stage compared to advanced stage tumours. At advanced stage, we observed a negative correlation with CCL22 levels and Th1/2 cytokine expression. We found a positive correlation between IL-6 concentration in ascites and residual disease after debulking. Additionally, IL-6 levels were remarkably higher at recurrence compared to primary advanced disease, which opens an opportunity for inhibition of IL-6 expression in the prevention of recurrence. Despite the heterogeneity of EOC and the complexity of cytokine functions, our results show that cytokine analysis in ascites may aid in understanding tumour-host interaction in EOC.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514148     DOI: 10.1016/j.ejca.2011.03.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  28 in total

1.  The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Petra L M Zusterzeel; Carl G Figdor; Leon F A G Massuger; Ruurd Torensma
Journal:  Cell Oncol (Dordr)       Date:  2013-08-09       Impact factor: 6.730

Review 2.  Aiming to immune elimination of ovarian cancer stem cells.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Carl G Figdor; Ruurd Torensma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

3.  Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.

Authors:  Nonna Kolomeyevskaya; Kevin H Eng; Anm Nazmul H Khan; Kassondra S Grzankowski; Kelly L Singel; Kirsten Moysich; Brahm H Segal
Journal:  Gynecol Oncol       Date:  2015-05-20       Impact factor: 5.482

4.  Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.

Authors:  Wei Wen; Wei Liang; Jun Wu; Claudia M Kowolik; Ralf Buettner; Anna Scuto; Meng-Yin Hsieh; Hao Hong; Christine E Brown; Stephen J Forman; David Horne; Robert Morgan; Mark Wakabayashi; Thanh H Dellinger; Ernest S Han; John H Yim; Richard Jove
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

5.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 6.  The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  J Mol Med (Berl)       Date:  2013-09-21       Impact factor: 4.599

7.  Oxidized lipids block antigen cross-presentation by dendritic cells in cancer.

Authors:  Rupal Ramakrishnan; Vladimir A Tyurin; Vladimir A Tuyrin; Filippo Veglia; Thomas Condamine; Andrew Amoscato; Dariush Mohammadyani; Joseph J Johnson; Lan Min Zhang; Judith Klein-Seetharaman; Esteban Celis; Valerian E Kagan; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2014-02-19       Impact factor: 5.422

8.  Profiling of cytokines in human epithelial ovarian cancer ascites.

Authors:  Isabelle Matte; Denis Lane; Claude Laplante; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

Review 9.  IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Bala K Kolli; Rajesh Dachepalli; Prem S Umar; Sameer K Rai; Namrata Singh; Pavan S Tavva; Donald W Weaver; Scott A Gruber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Antitumor effects and mechanisms of dendritic cells stimulated by sCD40L on ovarian cancer cells in vitro.

Authors:  Zheng-Mao Zhang; Xue-Mei Yang; Chao Zhang; Min-Jie Zhang; Xia Li; Feng-Hua Zhang; Shan Kang; Shi-Jie Wang; Bao-En Shan
Journal:  Onco Targets Ther       Date:  2013-05-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.